New antibiotic structures from fermentations

Expert Opinion on Therapeutic Patents

Volumn 20, Issue 10, 2010, Pages 1359-1371

  Singh, Sheo B ^a   Young, Katherine ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

antibiotics; fermentation; natural products; patents

Indexed keywords

AMYCOLAMICIN; ANTIBIOTIC AGENT; BISPOLIDE A1; BISPOLIDE A2; BISPOLIDE A3; BISPOLIDE B1; BISPOLIDE B2A; BISPOLIDE B2B; BISPOLIDE B3; DAPTOMYCIN; ELANSOLID A; ELANSOLID B1; ELANSOLID B2; ELANSOLID C1; FKI 3368; GLIONITRIN A; HEXACYCLINE; KIBDELONE B; PHILIPIMYCIN; PLATENCIN; PLATENSIMYCIN; THIAZOMYCIN; THIOSTREPTON; THUGGACIN A; THUGGACIN B; THUGGACIN C; UNCIALAMYCIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; UNNARMICIN A; UNNARMICIN C;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL ACTIVITY; DOSE RESPONSE; DRUG ISOLATION; DRUG SCREENING; DRUG STRUCTURE; FERMENTATION; KIDNEY INFECTION; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; REVIEW; STAPHYLOCOCCUS INFECTION; STREPTOCOCCUS PNEUMONIAE; STREPTOMYCES;

ANTI-BACTERIAL AGENTS; BIOLOGICAL PRODUCTS; DAPTOMYCIN; DRUG DESIGN; FERMENTATION; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS;

EID: 77956688537     PISSN: 13543776     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543776.2010.509347     Document Type: Review

References (45)

1. National Nosocomial Infections Surveillance (NNIS) system report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control 2004;32:470-485
2. Talbot GH, Bradley J, Edwards JE Jr, et al. Bad bugs need drugs: an update on the development pipeline from the antimicrobial availability task force of the Infectious Diseases Society of America. Clin Infect Dis 2006;42:657-668
3. Spellberg B, Guidos R, Gilbert D, et al. The epidemic of antibiotic-resistant infections: a call to action for the medical community from the Infectious Diseases Society of America. Clin Infect Dis 2008;46:155-164
4. Klevens RM, Morrison MA, Nadle J, et al. Invasive methicillin-resistant Staphylococcus aureus infections in the United States. J Am Med Assoc 2007;298:1763-1771
5. Singh SB, Barrett JF. Empirical antibacterial drug discovery-foundation in natural products. Biochem Pharmacol 2006;71:1006-1015
6. Payne DJ, Gwynn MN, Holmes DJ, et al. Drugs for bad bugs: confronting the challenges of antibacterial discovery. Nat Rev Drug Discov 2007;6:29-40
7. Merck & Co., Inc. Antibiotic compound. WO2005009391A2, 2005
8. Wang J, Soisson SM, Young K, et al. Platensimycin is a selective FabF inhibitor with potent antibiotic properties. Nature 2006;441:358-361
9. Merck & Co., Inc. Antibiotic compound. WO2005115400A2, 2005
10. Wang J, Kodali S, Lee SH, et al. Platencin is a dual fabf and fabh inhibitor with potent in vivo antibiotic properties. Proc Natl Acad Sci USA 2007;104:7612-7616
11. Singh SB, Jayasuriya H, Ondeyka JG, et al. Isolation, structure, and absolute stereochemistry of platensimycin, a broad spectrum antibiotic discovered using an antisense differential sensitivity strategy. J Am Chem Soc 2006;128:11916-20, 15547
12. Jayasuriya H, Herath KB, Zhang C, et al. Isolation and structure of platencin: a novel FabH and FabF dual inhibitor with potent broad spectrum antibiotic activity produced by Streptomyces platensis MA7339. Angew Chem Int Ed 2007;46:4684-4688
13. Herath KB, Attygalle AB, Singh SB. Biosynthetic studies of platensimycin. J Am Chem Soc 2007;129:15422-15423
14. Herath K, Attygalle AB, Singh SB. Biosynthetic studies of platencin. Tetrahedron Lett 2008;49:5755-5758
15. Merck & Co., Inc. Antibiotic compound. WO2006086012A2, 2006
16. Jayasuriya H, Herath K, Ondeyka JG, et al. Isolation and structure elucidation of thiazomycin-a potent thiazolyl peptide antibiotic from Amycolatopsis fastidiosa. J Antibiot (Tokyo) 2007;60:554-564
17. Singh SB, Occi J, Jayasuriya H, et al. Antibacterial evaluations of thiazomycin-a potent thiazolyl peptide antibiotic from Amycolatopsis fastidiosa. J Antibiot (Tokyo) 2007;60:565-571
18. Zhang C, Zink DL, Ushio M, et al. Isolation, structure, and antibacterial activity of thiazomycin A, a potent thiazolyl peptide antibiotic from Amycolatopsis fastidiosa. Bioorg Med Chem 2008;16:8818-8823
19. Zhang C, Herath K, Jayasuriya H, et al. Thiazomycins, thiazolyl peptide antibiotics from Amycolatopsis fastidiosa. J Nat Prod 2009;72:841-847
20. Constantine KL, Mueller L, Huang S, et al. Conformation and absolute configuration of nocathiacin I determined by NMR spectroscopy and chiral capillary electrophoresis. J Am Chem Soc 2002;124:7284-7285
21. Li W, Leet JE, Ax HA, et al. Nocathiacins, new thiazolyl peptide antibiotics from Nocardia sp. I. Taxonomy, fermentation and biological activities. J Antibiot (Tokyo) 2003;56:226-231
22. Merck & Co., Inc. Antibiotic compound. WO2008024285A2
23. Zhang C, Occi J, Masurekar P, et al. Isolation, structure, and antibacterial activity of philipimycin, a thiazolyl peptide discovered from Actinoplanes philippinensis MA7347. J Am Chem Soc 2008;130:12102-12110
24. Recombinogen Ltd. Cyclic lipopeptide. WO2007072082A1; 2007
25. Nicholas Piramal India Ltd. Novel antibacterial compounds. WO2007119201A2; 2007
26. Novobiotic. Novel macrocyclic lactams. US2009/0149395A1; 2009
27. Microbial Chemistry Research Foundation. New compound amycolamicin, method for producing the same and use of the same. 2009203195A; 2009
28. University of British Columbia. Novel enedieyne compound and uses thereof. WO2007038868A2; 2007
29. Davies J, Wang H, Taylor T, et al. Uncialamycin, a new enediyne antibiotic. Org Lett 2005;7:5233-5236
30. The University of Queensland and Microbial Screening Technologies PTY Ltd. Polyketide xanthones and uses thereof. WO2207095696A1; 2007
31. Ratnayake R, Lacey E, Tennant S, et al. Kibdelones: novel anticancer polyketides from a rare Australian Actinomycete. Chem Eur J 2007;13:1610-1619
32. Kitasato University. Novel compound, process for production thereof, and use thereof. WO2009034156A1; 2009
33. Taro Pharmaceuticals. Novel Streptomyces-derived antimicrobial compound and method of using same against antibiotic-resistant bacteria. WO2007127293A2; 2007
34. Panstwowy Zaklad Higieny. An inhibitor of DD-peptidase and its use as antibiotic or anticancer drug. WO2009028972A1; 2009
35. Helmholtz-Zentrum fur Infektionsforschung GmbH. Thuggacin-type macrolide antibiotics and their use as antimycobacterial agents. WO2008068127A1; 2008
36. Helmholtz-Zentrum fur infektionsforschung GmbH. Elansolids, novel natural metabolites of flxibacter and antibiotically active derivatives. EP2093212A1; 2008
37. Korea Institute of Science and Technology. The co-culture method of Sphingomonas sp bacterial strain and Aspergillus sp. fungus strain, new anti-cancer and antibiotic glionitrins derived from this co-culture method, and pharmaceutical composition containing glionitrins or pharmaceutically acceptable salt thereof as an active ingredient. WO2009066876A2; 2009
38. Park HB, Kwon HC, Lee CH, et al. Glionitrin A, an antibiotic-antitumor metabolite derived from competitive interaction between abandoned mine microbes. J Nat Prod 2009;72:248-252
39. Nimura Genetic Solutions Co., Ltd and Forest Research Institute Malaysia. Novel antibiotics, bispolides A1, A2, and A3 and bispolides B1, B2a, B2b, and B3 and methods for producing the antibiotics. EP2035758A1; 2007
40. Okujo N, Iinuma H, George A, et al. Bispolides, novel 20-membered ring macrodiolide antibiotics from microbispora. J Antibiot (Tokyo) 2007;60:216-219
41. Marine Biotechnology Institute Co., Ltd. Novel antibiotics. JP2007223969; 2007
42. Oku N, Kawabata K, Adachi K, et al. Unnarmicins A and C, new antibacterial depsipeptides produced by marine bacterium Photobacterium sp. MBIC06485. J Antibiot (Tokyo) 2008;61:11-17
43. Marine Biotechnology Institute Co., Ltd. Novel antibiotics. JP2007230911; 2007
44. Meiji Seika Kaisha, Ltd. Novel antibiotic SF2847, method of preparing it and medicinal compositions. JP2007097548; 2007
45. Julius-Maximilians-Universitaat Wuerzburg and Johannes Gutenberg-universitat Mainz and Stiftung Alfred Wergener Institut fur polar und Meeresforschung. Tajixanthone hydrate and tajixanthone hydrate derivatives, biological activities thereof, and use thereof. WO2005003085; 2005